Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Edwards Lifesciences (EW)

Edwards Lifesciences Reports Q3 2026 Sales of $1.72 Billion and Raises Full-Year Guidance

Positive Impact 4 of 5 guidance

Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase compared to the prior year. Driven by strong procedure volumes and robust performance across its businesses, the company raised its full-year 2026 sales growth and adjusted EPS guidance.

Key points

  • Q3 sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%.
  • Q3 EPS was $0.53, while adjusted EPS reached $0.80, up 19% versus the prior year.
  • Full-year 2026 sales growth guidance was increased to approximately 11.5% from the previous 10% to 11% range.
  • Adjusted EPS guidance for 2026 was raised to a range of $2.97 to $3.05.

The filing

CompanyEdwards Lifesciences (EW)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:21 PM ET
Accession number0001099800-26-000053

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 4, 2026, 5:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.